Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

INCY
Incyte Genomics Inc
stock NASDAQ

At Close
May 16, 2025 3:59:30 PM EDT
63.29USD+0.844%(+0.53)44,334
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 16, 2025 9:02:30 AM EDT
63.89USD+1.801%(+1.13)511
After-hours
May 16, 2025 4:00:30 PM EDT
63.31USD+0.032%(+0.02)14,176
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 28, 2022
11:10AM EST  Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema   Benzinga
08:16AM EST  Eli Lilly and Company (LLY) said, based on top-line efficacy results from two pivotal phase 3 trials (SLE-BRAVE-I and II), the company has decided to discontinue the phase 3 development program for OLUMIANT in lupus. The company is working with investigators to appropriately conclude the phase 3 SLE long-term extension trial, SLE-BRAVE-X.   RTTNews
08:05AM EST  Eli Lilly And Incyte Announce Decision To Discontinue Phase 3 Development Program For OLUMIANT In Lupus   Benzinga
08:03AM EST  Lilly Decides To Discontinue Phase 3 Development Program For OLUMIANT In Lupus   RTTNews
08:01AM EST  Updates on OLUMIANT(r) (baricitinib) Phase 3 lupus program and FDA review for   PR Newswire
Jan 26, 2022
07:07AM EST  Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus   Benzinga
Jan 25, 2022
04:36PM EST  Merus Appoints Shannon Campbell As Chief Commercial Officer And Regains Worldwide Rights To MCLA-145   Benzinga
04:30PM EST  Merus Appoints Shannon Campbell as Chief Commercial Officer and   GlobeNewswire Inc
Jan 24, 2022
02:41AM EST  Innovent Biologics Inc. (IVBXF.OB) said Monday that the Hong Kong Department of Health has approved Pemazyre or pemigatinib for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.   RTTNews
Jan 18, 2022
02:32PM EST  Where Incyte Stands With Analysts   Benzinga
08:00AM EST  Incyte to Report Fourth Quarter and Year-End 2021 Financial Results   Business Wire
06:38AM EST  RBC Capital Upgrades Incyte to Outperform, Raises Price Target to $90   Benzinga
Dec 15, 2021
09:07AM EST  Incyte's Topical JAK Inhibitor Under Priority FDA Review For Depigmented Skin Disorder   Benzinga
Dec 14, 2021
04:31PM EST  Incyte Reports Acceptance, Priority Review For Supplemental New Drug Application For Ruxolitinib Cream As Treatment For Patients With Vitiligo   Benzinga
04:30PM EST  Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura(tm)) as a Treatment for Patients with Vitiligo   Business Wire
08:00AM EST  Incyte to Present at Upcoming Investor Conferences   Business Wire
Dec 13, 2021
06:29AM EST  Why Are Datadog, Zscaler, Airbnb, Fortinet, Lucid Trading Higher Premarket?   Benzinga
Dec 11, 2021
01:22PM EST  MorphoSys AG (MOR) and Incyte (INCY) announced the additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi) in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma or DLBCL.   RTTNews
12:21PM EST  MorphoSys and Incyte Announced Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma at ASH; Said Results Indicate Significant Overall Survival Improvement Compared With Pola-BR and R2   Benzinga
12:07PM EST  MorphoSys Announces Additional Results From RE-MIND2 Study Of Tafasitamab - Lenalidomide For DLBCL   RTTNews
12:00PM EST  MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(r)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma   Business Wire
09:21AM EST  Incyte Announced Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas at ASH 2021   Benzinga
Dec 6, 2021
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Nov 19, 2021
11:53AM EST  Expert Ratings For Incyte   Benzinga
10:09AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021   Benzinga
05:34AM EST  BMO Capital Initiates Coverage On Incyte with Market Perform Rating, Announces Price Target of $75   Benzinga
Nov 9, 2021
08:33AM EST  Lilly : OLUMIANT Long-Term Safety Profile Established Up To 9.3 Years In Analysis On Rheumatoid Arthritis   RTTNews
08:31AM EST  OLUMIANT(r) Long-Term Safety Profile Established Up to 9.3 Years in Integrated   PR Newswire
08:00AM EST  Incyte to Present at Upcoming Investor Conference   Business Wire
Nov 4, 2021
10:12AM EDT  Cellenkos Secures $15 Mln Series A Financing To Accelerate Development Of Transformation Cell-Based Therapies   RTTNews
10:07AM EDT  Cellenkos(r) Inc. Secures $15 Million Series A Financing to Accelerate the   PR Newswire
09:34AM EDT  JMP Securities Maintains Market Outperform on Incyte, Lowers Price Target to $108   Benzinga
Nov 3, 2021
09:19AM EDT  Oppenheimer Maintains Outperform on Incyte, Lowers Price Target to $109   Benzinga
Nov 2, 2021
10:54AM EDT  The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US   Benzinga
10:50AM EDT  Incyte Reaffirms FY21 Jakafi Net Product Sales $2.125B-$2.17B   Benzinga
10:49AM EDT  Incyte Q3 Adj. EPS $1.18 Beats $0.73 Estimate, Sales $812.99M Beat $738.77M Estimate   Benzinga
10:42AM EDT  A Peek Into The Markets: US Stock Futures Edge Lower; Fed Meeting In Focus   Benzinga
10:41AM EDT  Earnings Scheduled For November 2, 2021   Benzinga
10:37AM EDT  Incyte's Parsaclisib Application Under FDA Review For 3 Types Of Non-Hodgkin Lymphomas   Benzinga
07:11AM EDT  Incyte Q3 EPS $0.82 Vs Loss $0.07 Last Year   RTTNews
Nov 1, 2021
09:17AM EDT  Data From Incyte's Oncology Portfolio Accepted For Presentation At The Society For Immunotherapy Of Cancer 2021 Annual Meeting   Benzinga
07:03AM EDT  Incyte Announces Acceptance Of NDA for Parsaclisib For Three Types Of Relapsed or Refractory Non-Hodgkin Lymphomas   Benzinga
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 28, 2021
07:48AM EDT  Incyte Reports Validation Of European Marketing Authorization Application For Ruxolitinib Cream In Vitiligo   Benzinga
Oct 13, 2021
08:00AM EDT  Incyte to Report Third Quarter Financial Results   Business Wire
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Oct 1, 2021
02:29PM EDT  Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates   Benzinga
Sep 30, 2021
06:40AM EDT  Eli Lilly and Co. (LLY) and Incyte (INCY) announced Thursday detailed results from two pivotal Phase 3 trials of OLUMIANT (baricitinib) in treating Alopecia Areata or AA.   RTTNews
06:03AM EDT  Lilly Announces Detailed Results From Two Pivotal Phase 3 Trials Of BRAVE-AA1 And BRAVE-AA2 For Alopecia Areata   RTTNews
05:59AM EDT  Eli Lilly and Company And Incyte Announce OLUMIANT Significantly Improved Hair Regrowth To At Least 80% Scalp Coverage As Early As 24 Weeks Across First Completed Phase 3 Studies For Alopecia Areata   Benzinga
05:56AM EDT  OLUMIANT(r) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage   PR Newswire
Sep 28, 2021
08:18AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive   Benzinga
08:16AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments   Benzinga
Sep 27, 2021
06:20AM EDT  Syndax Partners With Incyte To Develop, Commercialize   RTTNews
06:03AM EDT  Syndax Pharma, Incyte Enters Exclusive Worldwide Collaboration And License Agreement To Develop Axatilimab   RTTNews
06:02AM EDT  Syndax Pharmaceuticals And Incyte Announce Global Collaboration To Develop And Commercialize Axatilimab For Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases   Benzinga
06:01AM EDT  Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases   PR Newswire
Sep 23, 2021
12:41PM EDT  Expert Ratings For Incyte   Benzinga
11:10AM EDT  Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America   Benzinga
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021   Benzinga
08:42AM EDT  Morgan Stanley Maintains Equal-Weight on Incyte, Lowers Price Target to $80   Benzinga
08:20AM EDT  BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer   Benzinga
07:57AM EDT  The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data   Benzinga
07:54AM EDT  10 Biggest Price Target Changes For Thursday   Benzinga
07:40AM EDT  Knight Therapeutics Enters Into Exclusive Supply And Distribution Agreement With Incyte For Tafasitamab And Pemigatinib In Latin America   Benzinga
07:27AM EDT  RBC Capital Maintains Sector Perform on Incyte, Lowers Price Target to $86   Benzinga
06:30AM EDT  SVB Leerink Upgrades Incyte to Market Perform, Lowers Price Target to $66   Benzinga
Sep 22, 2021
01:01PM EDT  Incyte Announces FDA Approval Of Jakafi For Treatment Of Chronic Graft-Versus-Host Disease   RTTNews
12:38PM EDT  Incyte Announces FDA Of Jakafi For Treatment Of Chronic Graft-Versus-Host Diseases   Benzinga
12:38PM EDT  Incyte Announces FDA Approval of Jakafi(r) (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)   Business Wire
12:11PM EDT  Shares of biotechnology company Incyte Corp.(INCY) are down 7 percent on Wednesday's trading despite the company receiving U.S. FDA's approval for its Opzelura cream for the short-term and non-continuous chronic treatment of patients with mild to moderate Atopic Dermatitis.   RTTNews
08:59AM EDT  Briacell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer   Benzinga
07:45AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs   Benzinga
Sep 21, 2021
11:31PM EDT  The U.S. Food and Drug Administration has approved Incyte Corp.'s (INCY) Opzelura or ruxolitinib cream for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable.   RTTNews
04:13PM EDT  Incyte Reports FDA Approval Of Opzelura Cream For Treatment Of Atopic Dermatitis   Benzinga
04:13PM EDT  Incyte Announces U.S. FDA Approval of Opzelura(tm) (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)   Business Wire
03:21PM EDT  Incyte Shares Halted With Code News Pending Ahead Of Likely Ruling On Co.'s New Drug Application For Ruxolitinib; PDUFA Dates Had Been Set For 2 Co. Applications As Sept. 21, 22   Benzinga
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 20, 2021
01:46PM EDT  Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada   Benzinga
Sep 19, 2021
09:46AM EDT  The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions and Conference Presentations In The Spotlight   Benzinga
Sep 17, 2021
04:00PM EDT  (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma   PR Newswire
Sep 14, 2021
10:27AM EDT  Price Over Earnings Overview: Incyte   Benzinga
09:10AM EDT  Nimble Therapeutics, Incyte Expand Strategic Research Collaboration To 'Discover Additional Novel Peptide Therapeutics;' Terms Not Disclosed   Benzinga
Sep 13, 2021
04:31PM EDT  Incyte Announces Ruxolitinib Cream Data Accepted For Presentation At The 2021 European Academy Of Dermatology And Venereology Virtual Congress   Benzinga
Sep 2, 2021
08:35AM EDT  FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know   Benzinga
Aug 27, 2021
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
06:20AM EDT  Incyte - MorphoSys's Diffuse Large B-Cell Lymphoma Drug Wins European Approval   Benzinga
Aug 26, 2021
11:23PM EDT  MorphoSys : EU Conditionally Approves Minjuvi -   RTTNews
04:02PM EDT  MorphoSys And Incyte Announce European Commission Approval Of Minjuvi In Combination With Lenalidomide For Treatment Of Adults With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma   Benzinga
Aug 24, 2021
08:44AM EDT  Incyte (INCY) said Health Canada has approved with conditions Minjuvi, or tafasitamab, in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The approval of Minjuvi is the first marketing authorization for the company in Canada.   RTTNews
08:36AM EDT  Incyte Announces Health Canada Approval Of Minjuvi (tafasitamab) In Combination With Lenalidomide For Treatment Of Adults With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma   Benzinga
08:32AM EDT  Incyte: Health Canada Approves Minjuvi In Combination With Lenalidomide For R/r Diffuse Large B-Cell Lymphoma   RTTNews
08:30AM EDT  Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma   PR Newswire
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
08:00AM EDT  Incyte to Present at Upcoming Investor Conference   Business Wire
06:37AM EDT  Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China   Benzinga
04:45AM EDT  Biopharmaceutical company Incyte Corp. (INCY) announced Tuesday that it has entered into a collaboration and license agreement with a unit of Hong Kong's InnoCare for the development and commercialization of tafasitamab, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in Greater China.   RTTNews
04:23AM EDT  Incyte Announces Commercialization Agreement With InnoCare For Tafasitamab In Greater China   RTTNews
Aug 16, 2021
03:14PM EDT  BriaCell Therapeutics Attacks Cancer with Novel Off-the-Shelf Immunotherapies   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 4, 2021
04:47AM EDT  SVB Leerink Maintains Underperform on Incyte, Lowers Price Target to $67   Benzinga
Aug 3, 2021
07:33AM EDT  Incyte Corporation (INCY) announced earnings for second quarter that dropped from the same period last year.   RTTNews
07:10AM EDT  Incyte Q2 GAAP EPS $0.67; Non-GAAP EPS $0.80   RTTNews
07:07AM EDT  Incyte Narrows FY21 Jakafi Net Product Revenue Guidance From $2.125B-$2.2B To $2.125B-$2.17B   Benzinga
07:06AM EDT  Incyte Q2 Adj. EPS $0.80 Beats $0.75 Estimate, Sales $696.00M Beat $686.98M Estimate   Benzinga
06:37AM EDT  Eli Lilly and Co. (LLY) and Incyte (INCY) Tuesday said that new data from Phase 3 COV-BARRIER sub-study indicated that baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation.   RTTNews
06:08AM EDT  Eli Lilly And Incyte Announce Baricitinib Reduced Deaths Among Patients With Covid-19 Receiving Invasive Mechanical Ventilation   Benzinga
06:05AM EDT  Eli Lilly, Incyte Announce Results From Additional Cohort Of 101 Adult Patients From COV-BARRIER Trial   RTTNews
06:01AM EDT  Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19   PR Newswire
03:52AM EDT  Earnings Scheduled For August 3, 2021   Benzinga
Aug 2, 2021
06:10PM EDT  Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates   Benzinga
10:58AM EDT  A Preview Of Incyte's Earnings   Benzinga
Jul 29, 2021
01:37PM EDT  Eli Lilly-Incyte's Rheumatoid Arthritis Drug Gets OK From FDA For Solo Use In Hospitalized COVID-19 Patients   Benzinga
11:37AM EDT  FDA Late Wednesday Approved Eli Lilly And Incyte Arthritis Drug Baricitinib, In Combination With Remdesivir, To Treat COVID-19   Benzinga
09:45AM EDT  The U.S. Food and Drug Administration has broadened the Emergency Use Authorization or EUA for baricitinib to allow for treatment with or without remdesivir, whereas the EUA was previously restricted to use only in combination with remdesivir, Eli Lilly and Co. (LLY) and Incyte (INCY) said in a statement on Thursday.   RTTNews
09:28AM EDT  Lilly : FDA Broadens Existing Emergency Use Baricitinib In Patients Hospitalized With COVID-19 Requiring Oxygen   RTTNews
Jul 26, 2021
06:29AM EDT  FDA Strikes Off Incyte's Retifanlimab Application In Anal Cancer   Benzinga
Jul 23, 2021
11:15PM EDT  Incyte : FDA Issues Complete Response Letter For Retifanlimab   RTTNews
04:40PM EDT  Incyte Provides Regulatory Update On Retifanlimab For Treatment Of Patients With Squamous Cell Carcinoma Of Anal Canal   RTTNews
04:31PM EDT  Incyte Says FDA Has Issued Complete Response Letter Regarding Retifanlimab; Says FDA Cannot Approve Application In Present Form   Benzinga
04:30PM EDT  Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)   Business Wire
Jul 20, 2021
03:28PM EDT  Benchmark Upgrades Incyte After Stock Selloff   Benzinga
10:14AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021   Benzinga
07:42AM EDT  Benchmark Upgrades Incyte to Buy, Announces $89 Price Target   Benzinga
Jul 16, 2021
01:57PM EDT  AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA   Benzinga
10:34AM EDT  The U.S. Food and Drug Administration will not meet the Prescription Drug User Fee Act or PDUFA action date for the supplemental new drug application or sNDA for baricitinib for the treatment of adults with moderate to severe atopic dermatitis. The delay is related to the FDA's ongoing assessment of JAK inhibitors, Eli Lilly and Co. (LLY) and Incyte (INCY) said in a statement.   RTTNews
10:04AM EDT  Lilly And Incyte : FDA Will Not Meet PDUFA Action Date For SNDA For Baricitinib For Atopic Dermatitis Treatment   RTTNews
10:04AM EDT  Eli Lilly And Co, Incyte Say FDA Will Not Meet Prescription Drug User Fee Act Action Date For Supplemental New Drug Application For Baricitinib For Treatment Of Adults With Moderate To Severe Atopic Dermatitis   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
08:00AM EDT  Incyte to Report Second Quarter Financial Results   Business Wire
07:12AM EDT  Incyte's Ruxolitinib Shows Better Outcomes Regardless Of Organs Affected In GvHD Patients   Benzinga
Jul 14, 2021
05:01PM EDT  Incyte Announces Highlights Publication Of Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi) in Chronic Graft-Versus-Host Disease   Benzinga
08:30AM EDT  BriaCell's Early-Stage Combination Study In Advanced Breast Cancer Starts Enrollment   Benzinga
Jul 9, 2021
09:47AM EDT  Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer   Benzinga
Jun 29, 2021
03:28PM EDT  EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters   Benzinga
Jun 25, 2021
09:13AM EDT  FDA AdCom In Favor Of Delaying Incyte's Retifanlimab Approval In Anal Cancer   Benzinga
08:05AM EDT  Incyte, MorphoSys Get Positive CHMP Opinion For   RTTNews
07:50AM EDT  MorphoSys, Incyte Announce Positive CHMP Opinion For Tafasitamab In Combination With Lenalidomide   RTTNews
07:42AM EDT  Incyte And MorphoSys Announce Positive CHMP Opinion For Tafasitamab In Combination With Lenalidomide For Treatment Of Adults With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma   Benzinga
07:21AM EDT  RBC Capital Maintains Sector Perform on Incyte, Lowers Price Target to $88   Benzinga
Jun 24, 2021
03:56PM EDT  An FDA panel has recommended that regulatory decision on Incyte's (INCY) Retifanlimab injection should be delayed until more data are available.   RTTNews
03:32PM EDT  UPDATE: Incyte Says FDA Committee Voted 13-4 To Delay Regulatory Decision On Retifanlimab Until Further Data Are Available   Benzinga
03:32PM EDT  Incyte Highlights Outcome Of FDA Oncologic Drugs Advisory Committee Meeting Reviewing Retifanlimab As Treatment For Patients With Squamous Cell Carcinoma Of The Anal Canal   Benzinga
08:12AM EDT  The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO   Benzinga
Jun 21, 2021
08:50AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Monday, Jun. 21, 2021: WISH, INCY, CFLT, BBBY, PLUG   Benzinga
Jun 15, 2021
07:37AM EDT  07:37 Tuesday, June 15, 2021William Blair (RTTNews) - William Blair Reiterates Incyte Corporation (INCY) At Outperform   RTTNews
Jun 11, 2021
08:20AM EDT  Incyte Corp. (INCY) said Friday that the U.S. Food and Drug Administration has extended the review period for the New Drug Application or NDA for ruxolitinib cream for the treatment of atopic dermatitis.   RTTNews
07:59AM EDT  Incyte: FDA Extends Review Period For NDA For Ruxolitinib Cream For Atopic Dermatitis   RTTNews
07:32AM EDT  Incyte Announces FDA Has Extended New Drug Application Review Period For Ruxolitinib Cream For Treatment Of Atopic Dermatitis To Sept. 21 To Allow Time To Review Additional Analyses Submitted In Response To FDA's Information Request   Benzinga
Jun 8, 2021
08:14AM EDT  Biopharmaceutical company Incyte Corp. (INCY) announced Tuesday that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi) for the treatment of adult and pediatric patients 12 years and older with steroid-refractory chronic graft-versus-host disease (GVHD).   RTTNews
07:37AM EDT  Incyte: FDA Extends Review Period For SNDA For Ruxolitinib   RTTNews
07:32AM EDT  Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib in Chronic Graft-Versus-Host Disease   Benzinga
Jun 4, 2021
01:46PM EDT  Incyte, MorphoSys Announce 3-Year Results From Phase 2 L-MIND Study Of Tafasitamab In Combination With Lenalidomide For Treatment Of Relapsed Or Refractory DLBCL   Benzinga
Jun 2, 2021
12:06PM EDT  Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial   Benzinga
10:38AM EDT  Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates   Benzinga
09:15AM EDT  BriaCell Stock Doubles After Reporting Overall Survival Benefit in Pretreated Breast Cancer Patients   Benzinga
Jun 1, 2021
07:31PM EDT  OLUMIANT(r) Improved Pain, Physical Function and Morning Joint Stiffness in   PR Newswire
05:31PM EDT  Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates   Benzinga
May 20, 2021
08:00AM EDT  Incyte to Present at Upcoming Investor Conferences   Business Wire
06:26AM EDT  Incyte To Present Positive Primary Analysis From Phase 2 OPTIC Study Of Ponatinib   RTTNews
06:03AM EDT  Positive Primary Analysis From The Phase 2 OPTIC Study of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia To Be Presented at the 2021 ASCO Annual Meeting   Benzinga
May 19, 2021
05:25PM EDT  Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021   Benzinga
May 17, 2021
12:36PM EDT  Incyte's Ruxolitinib Cream Aces Late-Stage Vitiligo Trials, Teeing Up Regulatory Submissions   Benzinga
08:13AM EDT  Incyte Corp. (INCY) announced Monday positive topline results from its pivotal Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream, an investigational, nonsteroidal, anti-inflammatory, JAK inhibitor, topical therapy, in adolescent and adult patients (age 12 years) with vitiligo.   RTTNews
07:56AM EDT  Incyte Says Primary And Key Secondary Endpoints Met In Both TRuE-V1 And TRuE-V2 Studies   RTTNews
07:32AM EDT  Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo; Co. Reports 'Primary and key secondary endpoints met in both TRuE-V1 and TRuE-V2 studies'   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
04:05PM EDT  Incyte, MorphoSys Report First Patient Dosed In Phase 3 frontMIND Study Evaluating Tafasitamab Combo As Treatment For Diffuse Large B-Cell Lymphoma   Benzinga
May 5, 2021
08:28AM EDT  Morgan Stanley Maintains Equal-Weight on Incyte, Lowers Price Target to $85   Benzinga
May 4, 2021
12:17PM EDT  Incyte's Q1 Jakafi Sales Hit By Pandemic; Reaffirms 2021 Guidance   Benzinga
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
07:29AM EDT  Recap: Incyte Q1 Earnings   Benzinga
07:11AM EDT  Incyte Q1 Non-GAAP EPS $0.67 Vs Loss $2.86 Last Year   RTTNews
07:09AM EDT  Incyte Reaffirms FY21 Jakafi Net Product Revenues $2.125B-$2.2B   Benzinga
07:08AM EDT  Incyte Q1 Adj. EPS $0.67 Beats $0.64 Estimate, Sales $605.00M Miss $659.24M Estimate   Benzinga
May 3, 2021
08:20AM EDT  Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology Virtual Meeting 2021   Benzinga
08:20AM EDT  Incyte To Present Data On Ruxolitinib Cream In Atopic Dermatitis Accepted At Society For Investigative Dermatology Virtual Meeting 2021   Benzinga
Apr 27, 2021
08:00AM EDT  Incyte to Present at Upcoming Investor Conference   Business Wire
Apr 26, 2021
08:01AM EDT  08:00 Monday, April 26, 2021William Blair (RTTNews) - William Blair Reiterates Incyte Corporation (INCY) At Outperform   RTTNews
Apr 23, 2021
01:20PM EDT  Incyte Announces New Ruxolitinib Data From Atopic Dermatitis and Vitiligo Studies   Benzinga
10:44AM EDT  Incyte : Olumiant Shows Improvements In Severity And   RTTNews
10:06AM EDT  Eli Lilly Reports OLUMIANT Showed Improvements In Severity, Extent Of Atopic Dermatitis, Other Patient-Reported Outcomes In Phase 3 Analyses   Benzinga
10:04AM EDT  Lilly : OLUMIANT Shows Improvements In Severity And Extent Of Atopic Dermatitis In Phase 3 Study Analyses   RTTNews
10:02AM EDT  Incyte Highlights New Findings From Randomized Phase 2 Study Of Ruxolitinib Cream In Patients With Vitiligo   Benzinga
10:02AM EDT  Incyte Reports New Findings From Pooled Analyses Of Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream In Patients With Atopic Dermatits   Benzinga
10:01AM EDT  Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses   PR Newswire
Apr 20, 2021
08:16AM EDT  Incyte To Present multiple Abstracts At Academy of Dermatology Virtual Meeting Experience   Benzinga
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
07:52AM EDT  Eli Lilly and Company (LLY) and Incyte (INCY) today reported the second late-stage study of baricitinib met primary endpoint of improved hair regrowth in patients with alopecia areata (AA).   RTTNews
06:53AM EDT  Eli Lilly And Incyte Announce Baricitinib Improved Hair Regrowth For Alopecia Areata Patients In Second Phase 3 Study   Benzinga
06:48AM EDT  Lilly, Incyte Reports Results From Second Phase 3 Trial (BRAVE-AA1) Of Baricitinib In Adults With Severe Alopecia Areata   RTTNews
06:45AM EDT  Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata   PR Newswire
Apr 19, 2021
10:37PM EDT  Incyte (INCY) and MorphoSys AG (MOR) said that the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL).   RTTNews
04:21PM EDT  MorphoSys, Incyte Announce First Patient Dosed In Phase 3 InMIND Study   RTTNews
04:02PM EDT  Incyte And MorphoSys Announce First Patient Dosed In Phase 3 inMIND Study Evaluating Addition Of Tafasitamab To Lenalidomide And Rituximab In Relapsed Or Refractory Follicular Or Marginal Zone Lymphoma   Benzinga
Apr 16, 2021
04:37PM EDT  Incyte Corp Trial Did Not Meet Statistical Significance On Primary Endpoint   Benzinga
Apr 13, 2021
08:00AM EDT  Incyte to Report First Quarter Financial Results   Business Wire
Apr 8, 2021
08:14AM EDT  The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data   Benzinga
07:42AM EDT  Eli Lilly and Company (LLY) and Incyte (INCY) on Thursday said their late-stage study of baricitinib in hospitalized Covid-19 patients did not achieve the main goal.   RTTNews
07:41AM EDT  Eli Lilly-Incyte's Baricitinib Study In Hospitalized COVID-19 Patients Fails To Meet Main Goal   Benzinga
06:48AM EDT  Lilly, Incyte: Phase 3 COV-BARRIER Study Of Baricitinib Fails To Meet Statistical Significance On Primary Endpoint   RTTNews
06:47AM EDT  Lilly And Incyte Announce Results From The Phase 3 COV-BARRIER Study Of Baricitinib In Hospitalized Covid-19 Patients' The Co,'s Report 'The trial did not meet statistical significance on the primary endpoint'   Benzinga
06:45AM EDT  Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of   PR Newswire
Apr 7, 2021
07:58AM EDT  The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award   Benzinga
Apr 6, 2021
04:31PM EDT  Eli Lilly, Incyte Report FDA Extended Review Period For Supplemental New Drug Application For Baricitnib For Treatment Of Adults With Moderate To Severe Atopic Dermatitis By 3 Months To Early Q3'21   Benzinga
04:30PM EDT  Application for baricitinib for the treatment of moderate to severe atopic dermatitis   PR Newswire
Apr 5, 2021
08:06AM EDT  Morgan Stanley Maintains Equal-Weight on Incyte, Lowers Price Target to $86   Benzinga
Mar 29, 2021
02:35PM EDT  Incyte's Pemazyre Wins European Approval For Bile Duct Cancer   Benzinga
12:05PM EDT  Incyte Announces The European Commission Approval Of Pemazyre (pemigatinib) As Treatment For Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Or Rearrangement   Benzinga
Mar 23, 2021
05:15AM EDT  Incyte Announced Japan Approval of Pemazyre for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy   Benzinga
Mar 19, 2021
07:13AM EDT  Incyte's Ruxolitinib Fails To Beat Placebo In Improving Mortality In Critically-Ill COVID-19 Patients   Benzinga
Mar 18, 2021
04:33PM EDT  Incyte Says Expanded Access Program To Allow Eligible US Patients To Receive Ruxolitinib Will Be Discussed With FDA   Benzinga
04:31PM EDT  Incyte Announces Phase 3 DEVENT Study Evaluating Ruxolitinib In COVID-19 Associated Acute Respiratory Distress Syndrome Did Not Meet Primary Endpoint   Benzinga
Mar 3, 2021
11:49AM EST  Cramer Advises Viewers On Palo Alto, Pfizer, Zillow And More   Benzinga
09:43AM EST  Eli Lilly/Incyte's Baricitinib Shows Benefit In Patchy Hair Loss Disorder   Benzinga
07:35AM EST  Eli Lilly and Company (LLY) and Incyte (INCY) announced positive topline results from the late-stage study of baricitinib for the treatment of adults with severe alopecia areata (AA), an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress.   RTTNews
06:47AM EST  Lilly : Phase 3 Study On Baricitinib Meets Primary Endpoint Of Hair Regrowth Across Both Dosing Regimens   RTTNews
06:47AM EST  Eli Lilly And Incyte Announce Results From Phase 3 Study Of Baricitinib In Alopecia Areata; Both Doses Met Primary Efficacy Endpoint   Benzinga
06:45AM EST  Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3   PR Newswire
Feb 26, 2021
08:17AM EST  The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida   Benzinga
Feb 22, 2021
08:08AM EST  Incyte Announces Acceptance and Priority Review of sNDA for Jakafi (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease   Benzinga
Feb 19, 2021
10:32AM EST  FDA Accepts Incyte's Ruxolitinib Cream US Application For Chronic Skin Disease   Benzinga
08:02AM EST  Incyte Announces Acceptance And Priority Review Of NDA For Ruxolitinib Cream For Atopic Dermatitis   Benzinga
Feb 11, 2021
08:00AM EST  Incyte to Present at Upcoming Investor Conference   Business Wire
Feb 10, 2021
10:05AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2021   Benzinga
08:11AM EST  Morgan Stanley Maintains Equal-Weight on Incyte, Lowers Price Target to $93   Benzinga
07:06AM EST  SVB Leerink Downgrades Incyte to Underperform, Lowers Price Target to $70   Benzinga
Feb 9, 2021
10:03AM EST  Incyte shares were trading higher after the company reported better-than-expected Q4 EPS and sales results.   Benzinga
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
07:29AM EST  Incyte Corp. (INCY) on Tuesday reported a net income of $149.85 million or $0.68 per share for the fourth quarter, up from $111.01 million or $0.51 per share in the prior-year quarter.   RTTNews
07:24AM EST  Incyte Corporation (INCY) released earnings for its fourth quarter that advanced from the same period last year.   RTTNews
07:13AM EST  Recap: Incyte Q4 Earnings   Benzinga
07:12AM EST  Incyte Sees Jakafi Net Product Sales $2.125B-$2.200B   Benzinga
07:12AM EST  Incyte Q4 GAAP EPS $0.68; Non-GAAP EPS $0.93   RTTNews
07:11AM EST  Incyte Q4 EPS $0.93 Beats $0.75 Estimate, Sales $789.51M Beat $662.94M Estimate   Benzinga
04:05AM EST  Earnings Scheduled For February 9, 2021   Benzinga
Feb 6, 2021
12:42PM EST  The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight   Benzinga
Jan 29, 2021
01:38PM EST  Incyte Announces Positive CHMP Opinion For Pemigatinib   Benzinga
Jan 21, 2021
04:32PM EST  Incyte Announces Acceptance And Priority Review Of BLA For Retifanlimab As A Potential Treatment For Patients With Squamous Cell Carcinoma Of The Anal Canal   Benzinga
Jan 19, 2021
08:01AM EST  Incyte to Report Fourth Quarter and Year-End 2020 Financial Results   Business Wire
Jan 13, 2021
07:25AM EST  The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations   Benzinga
Jan 12, 2021
10:00PM EST  MorphoSys AG (MOR) and Incyte (INCY) said that Health Canada has accepted the New Drug Submission or NDS for tafasitamab, an anti-CD19 antibody.   RTTNews
04:31PM EST  MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab   Benzinga
04:01PM EST  Incyte and MorphoSys Announce Acceptance By Health Canada Of New Drug Submission For Tafasitamab   Benzinga
04:00PM EST  Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC